KMagdum C. By the addition of superdisintegrants the disintegration time increased significantly P. The drug content uniformity was in between Results revealed that among the 6 formulations, the formulation S3 containing 7. Indexing Go to indexing.
The in-vitro disintegration time of fast dissolving tablets were found to be 17 to 71 sec. Rapid disintegration within several minutes was observed in all the formulations.
S3 shown disintegration time of 9. The values of pre-compression parameters evaluated were within prescribed limits and indicated good free flowing property. Journal Statastics 14 Visitors Online. Pharm can submit their Project abstract.
Valsartan fast dissolving tablet formulations prepared by the direct compression method by using crosspovidone synthetic and gum karaya natural superdisintegrant. All the post compression parameters are evaluated were prescribed limits and results were within IP acceptable limits. In the present research work an attempt has been made to prepare fast dissolving tablets of valsartan by using direct compression technique using sodium starch glycolate, croscarmellose sodium, kyronT and crospovidone are used as a superdisintegrants.
Trake Your Article Trake your article. Fast dissolving drug delivery is currently the gold standard in the pharmaceutical industry where it is regarded as the fastest, safest,convenient and most economic method of drug delivery having the highest patient compliance and preferred over conventional tablets.
Abstract Valsartan is an angiotensin II type 1 receptor antagonist indicated in the treatment of hypertension and mild to moderate heart failure of ischamatic or cardiomyopatheic origin. The prepared tablets were evaluated for pre and post-compressional parameters.
Processing fees will not be charged against Online publication of abstract. The present study has a design the formulation of the valsartan fast dissolving tablets and evaluate which was prepared by using synthetic and natural superdisintegrants.
Research Scholars of M. Valsartan is an angiotensin II type 1 receptor antagonist indicated in the treatment of hypertension and mild to moderate heart failure of ischamatic or cardiomyopatheic origin. This work is licensed under a Creative Commons Attribution 4. Formulations were evaluated for precompressional and postcompressional parameters like uniformity of weight, thickness, hardness, friability, drug content, wetting time, water absorption ratio, in vitro dispersion time, in vitro disintegration time and in vitro dissolution study.